

**Registered number: NI070062**  
**HMRC Charity number: XT5406**  
**Charity Commission (Northern Ireland) number: NIC105839**

**The McClay Foundation**  
**(a company limited by guarantee)**  
**Annual report and financial statements**  
**for the year ended 30 September 2024**

# **The McClay Foundation**

## **(a company limited by guarantee)**

### **Annual report and financial statements for the year ended 30 September 2024**

	Page(s)
Reference and administrative details of the Charity	1
Chairman's report	2
Trustees' report (incorporating the director's report)	3 - 15
Independent auditors' report to the members of The McClay Foundation	16 - 19
Statement of financial activities (incorporating income and expenditure account)	20
Balance sheet	21
Cash flow statement	22
Notes to the financial statements	23 - 31

# **The McClay Foundation** **(a company limited by guarantee)**

## **Reference and administrative details of the Charity**

### **Trustees/Directors**

A D Armstrong  
T Scott  
The McClay Foundation Corporate Trustee Limited  
(Directors listed below)  
A D Armstrong  
S Campbell  
J Irvine  
I Huddleston  
P Diamond  
D Clements (resigned 6 June 2024)  
H Stevenson  
E McAllister  
N Harkin  
K Stephens  
G McBurney

### **Registered office/Principal office**

Almac House  
20 Seagoe Industrial Estate  
Craigavon  
BT63 5QD

### **Bankers**

Danske Bank  
Donegall Square West  
Belfast  
BT1 6JS

### **Independent auditors**

PricewaterhouseCoopers (Northern Ireland) LLP  
Chartered Accountants and Statutory Auditors  
Merchant Square  
20-22 Wellington Place  
Belfast  
BT1 6GE

### **HMRC Charity number**

XT5406

### **Charity commission (Northern Ireland) number**

NIC105839

### **Solicitors**

BDB Pitmans Solicitors  
One Bartholomew Close  
London  
EC1A 7BL

### **Registered number**

NI070062

# **The McClay Foundation** **(a company limited by guarantee)**

## **Chairman's report for the year ended 30 September 2024**

The McClay Foundation's activities are progressing in line with the latest five-year strategic plan (2022-2027).

The Trustees have identified four strategic areas of focus:

- Innovation - Research and development of new medicines.
- Oncology research – targets and biomarkers.
- Dignity and Compassion - Research led care for those in end of life, or life limited circumstances.
- Health and Wellbeing - Activities to promote health and wellbeing in disenfranchised communities and geographical areas in the developed and the developing world.

This report illustrates the work we have done this year to demonstrate our long-term commitment to the principal objectives of The McClay Foundation and our desire to uphold Sir Allen McClay's wishes by continuing his legacy and vision to make a meaningful contribution to human health and wellbeing, worldwide.

The work of the McClay Foundation in the year ended 30 September 2024, working with many and varied partners to achieve its aims and objectives, has resulted in significant and measurable benefit to the health and wellbeing of many in society.



Alan Armstrong  
Chairman

27 February 2025

# **The McClay Foundation**

## **(a company limited by guarantee)**

### **Trustees' report for the year ended 30 September 2024 (incorporating the Directors' report)**

The Trustees, who are also directors of the charitable company for the purpose of the Companies Act 2006, present their Annual report and the audited financial statements for the year ended 30 September 2024. This report constitutes the Trustees' Report required under the Companies Act 2006 and the Charities Act (Northern Ireland) 2008.

The Trustees have adopted the provisions of the Companies Act 2006 and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their financial statements in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) effective 1 January 2015 - (Charities SORP (FRS 102)), in preparing the Annual report and financial statements of the charity.

### **Reference and administrative details of the charity, the Trustees, and advisors**

The Trustees of the charity are listed on page 1. The principal and registered office of the charity is also listed on page 1 together with details of the professional advisers and bankers.

### **Structure, governance, and management**

The McClay Foundation ("the charity" or "the Foundation") was incorporated as a company limited by guarantee on 31 July 2008. The company is exempt under this legislation from using "limited" as part of its name. It does not have a share capital and the liability of each member to contribute to the assets of the company is limited to £1. The charity registered with the Charity Commission in Northern Ireland on 22 June 2019, registration number NIC105839.

The charity is registered with the Companies Registrar registration number NI070062. It is also recognised as a charity by HM Revenue and Customs ("HMRC"), XT5406.

#### **Governance**

The role of the Trustees is to ensure that the charity is effectively governed; to ensure that the charity complies with all relevant legislation, its own Articles of Association and the requirements of good practice; and to ensure that the charity works to agreed strategic and operational plans.

The charity's governing documents are the Articles of Association (as amended in 2018) which assist the Trustees in the management of the charity.

The Articles of Association require that a Trustee shall hold office until the end of the Annual General Meeting held nearest in time to the third anniversary of his election. One third, or the nearest to one third, of Trustees must retire at each Annual General Meeting, those longest in office retiring first. A Trustee retiring by rotation shall be eligible for re-election. This is approved by a majority vote by the Trustees at the Annual General Meeting (in their capacity as company members). The Foundation ensures all its Trustees are trained under the various regulations.

#### **Risk management**

The Trustees have actively reviewed the major risks, business and operational, that the charity may face and confirm that systems have been established to mitigate significant risks. The charity has developed a risk register which is subject to regular review by the Trustees.

#### **Appointment of new Trustees**

New Trustees are recruited by open recruitment by existing Trustees to fulfil specific roles on the Board. The potential trustee is then interviewed by the Board regarding their willingness to become a trustee and their potential contribution to the Foundation is considered.

#### **Policy for the awarding of grants**

The Foundation's grant programmes are approved by Trustees. All programmes involve an application process. Applications are assessed by the Trustees, including robust assessment of governance. Final approval is sought at board meetings before decisions are shared with applicants. The applicants must sign up to Terms & Conditions before funding is released via bacs payment. All grantees must complete an evaluation report, outlining expenditure, performance, and impact on at least an annual basis.

# The McClay Foundation

## (a company limited by guarantee)

### Trustees' report for the year ended 30 September 2024 (incorporating the Directors' report) (continued)

#### Objectives and activities

**Our Vision** – To make meaningful improvement and advancement in human health.

**Our Mission** – To support those involved in advancing biomedical research, human health, and wellbeing around the world.

The objectives of the charity as laid out in the charity's governing documents are:

- the relief of poverty, unemployment and financial hardship by the generation and promotion of employment opportunities for the people of Northern Ireland;
- the advancement of health and healthcare by the support and encouragement of research and innovation in the field of healthcare and allied technologies;
- the advancement of the health and wellbeing of all people and specifically those in poor communities to enable them to access and benefit from the latest advances in healthcare;
- the prevention, control, and cure of disease by advancing the use of diagnostic tools and drugs; and
- to support and promote such educational purposes as the Trustees shall select, provided always that such purposes shall be exclusively charitable in law.

#### Guiding Principles

The Trustees of the Foundation have agreed to the following guiding principles to enable the Foundation to achieve its charitable purposes.

The Foundation will pursue strategic activities which demonstrate:

- Meaningful support that will enable the organisation and/or project to advance its objectives significantly and, simultaneously, advance the charitable purposes of the Foundation.
- A benefit that would not otherwise have been realised by the organisation, but for the support provided.
- Support for NI based organisations and/ or projects, where possible.

The main activities undertaken in relation to these objectives are outlined within the achievements and performance section. The Foundation's activities do not include social investment or the engagement of volunteers to meet the Foundation's charitable objectives.

#### Achievements and Performance

##### Strategic Focus Areas

The Trustees have agreed to apply these guiding principles to the following strategic areas:

1. Innovation - Research and development of new medicines.
2. Oncology research – Targets and biomarkers.
3. Dignity and Compassion - Research led care for those in end of life, or life limited circumstances.
4. Health and Wellbeing - Activities to promote health and wellbeing in disenfranchised communities and geographical areas in the developed and the developing world.

##### 1. Innovation - Research and Development of New Medicines

The Foundation is the majority shareholder of the Almac Group ("Almac" or "the Group") and monitors the activities of the Group ensuring it adheres to, and delivers on, the charitable objectives of the Foundation.

The overriding objectives of Almac are to:

- adhere to and deliver on the charitable objectives of The McClay Foundation
- ultimately benefit the wellbeing of patients through the research and development of new medicines; and
- develop and expand a world class Group of companies operating in the Pharmaceutical and Biotech sectors.

# The McClay Foundation

## (a company limited by guarantee)

### Trustees' report for the year ended 30 September 2024 (incorporating the Directors' report) (continued)

#### 1. Innovation - Research and Development of New Medicines (continued)

Thereby advancing Sir Allen McClay's legacy and his vision for The McClay Foundation and its charitable purposes, Almac's Strategic Goals include:

- remaining privately owned by The McClay Foundation;
- continuing Group wide innovation;
- achieving best-in-class business offerings;
- cultivating a desirable place to work;
- enabling the latest healthcare advances to be available to all;
- continuing the generation of employment opportunities and providing skills training for the people of Northern Ireland; and
- maintaining and improving profit margins to increase the amount available for reinvestment into the work of the Almac Group Limited and, by extension, the charitable objectives of The McClay Foundation.

#### Activities and Impact

<p><b>Almac Group</b></p>	<p>The Almac Group is an established contract development and manufacturing organisation which provides an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally. The Almac Group has continued to grow its employee base to approximately 7,500 people and has contributed to over 70% of US Food and Drug Administration (FDA) approved new molecular entities (NMEs) in the last 3-year period as the Group continues to work with all the top 25 BioPharma companies globally in the development of new medicines.</p> <p>The Almac Group is comprised of a number of business units, each of which contributes to the advancement of Almac's Strategic Goals and to the research and development of new medicines.</p> <p><b>Almac Discovery</b> is an independent, research driven drug discovery company, dedicated to the development of novel and innovative therapeutics.</p> <p><b>Almac Sciences</b> provides integrated services from development to commercial scale manufacture of advanced intermediates and Active Pharmaceutical Ingredients (API). Almac Sciences provides a range of services for small molecules and peptides and applies innovative biocatalysis and technology solutions which contribute to cost and time savings for its clients.</p> <p><b>Almac Pharma Services</b> provides expert pharmaceutical drug product development and manufacturing solutions, supporting all phases of clinical trials, through product launch and ongoing supply.</p> <p><b>Almac Diagnostics Services</b> is a global stratified medicine company specialising in biomarker driven clinical trials. Almac Diagnostics Services is focused on the discovery, development and commercialisation of diagnostic and companion diagnostic tests.</p> <p><b>Almac Clinical Services</b> is recognised as an innovative, global solutions provider within the specialised and complex market of clinical trial supply. Almac Clinical Services' integrated and adaptable solutions offer the most flexible approach to support the delivery of global clinical trials from protocol right through to patient delivery.</p> <p><b>Almac Clinical Technologies</b> is a global provider of Interactive Response Technology (IRT) and expert consultancy for the biopharmaceutical industry, empowering clinical trial sponsors to proactively manage sites, patients, and clinical supplies through our industry-leading technology solutions.</p> <p><b>Galen</b> develops, markets and sells a wide range of branded and generic pharmaceuticals and medical nutrition products.</p>
---------------------------	---

# The McClay Foundation

(a company limited by guarantee)

## Trustees' report for the year ended 30 September 2024 (incorporating the Directors' report) (continued)

<p>Almac Group (continued)</p>	<p>From a research and development perspective, companies within the Group have been engaged in the following activities over the past 12 months:</p> <ul style="list-style-type: none"> <li>○ The Wee1 inhibitor Debio-0123 and Akt inhibitor VAD-044 which Almac Discovery out-licensed for further development are both progressing well in clinical development.</li> <li>○ Almac Discovery continues to collaborate with both academia and other biotech companies to deepen its existing knowledge and skills in specific areas.</li> <li>○ Almac Discovery has nominated 3 Candidate Drugs, each ready to enter preclinical development. Almac Sciences completed the construction of a 28,000 sq ft facility to increase its peptide manufacturing operations by 30%. This facility expansion will enhance synthesis, purification and isolation capabilities and meet anticipated demand for clinical development and commercial products.</li> <li>○ Almac Sciences' affiliate, Arran Chemical Company, celebrated 40 years in operation. Arran is a named manufacturer of key building blocks that go into over 30 different commercial drugs ranging from products that are used to treat hypertension, cardiovascular issues, renal problems and epilepsy, among others.</li> <li>○ Almac Pharma Services supported pharmaceutical development activities for 70 projects and released over 400 batches of clinical trial material for use in clinical trials.</li> <li>○ Almac Pharma Services supported the launch of 12 new pharmaceutical drugs and over 150 new commercial SKUs, releasing over 6,000 batches of commercial drug product for patient use globally. These products address a wide range of previously unmet therapy areas and indications including blood cancer, brain tumours and epilepsy.</li> <li>○ Almac Pharma Services completed its first commercial operation from its Charnwood site, thereby broadening its existing commercial capabilities and capacity. In addition, Almac Pharma Services completed two major investment projects at its headquarter site in Craigavon – a bespoke 100,000 sq ft state-of-the-art, multi-product solid oral dose commercial manufacturing facility and a 32,000 sq ft custom-built high-volume facility that significantly increases commercial manufacturing and packaging of sachet drug product presentations.</li> <li>○ Almac Diagnostic Services opened a new 40,000 sq ft diagnostics development and manufacturing facility which allows it to expand all core service lines, including genomic services, product development and clinical testing. This new facility also provides dedicated manufacturing capacity which increases Almac Diagnostic Services' ability to manufacture and distribute Companion Diagnostic (CDx) kits on a commercial scale to support growing client demand.</li> <li>○ Almac Diagnostics launched a new diagnostic test product range focused on chronic disease. The first two products to be developed and validated for use within clinical trials include assays for PNPLA3 and HSD17B13, two genes implicated in the development of metabolic dysfunction-associated steatohepatitis (MASH) and metabolic dysfunction-associated fatty liver disease (MAFLD).</li> <li>○ Almac Clinical Services has seen growth in both revenue and the initiation of new clinical programmes. In particular, it has seen a record 12% growth in active clinical studies, including several major programmes to treat obesity.</li> <li>○ Almac Clinical Services is currently undertaking a major infrastructure expansion at its North American headquarters which will increase existing cold-chain capacity by 60% including additional refrigerated, ultra-low storage, and Just-In-Time processing capabilities.</li> <li>○ Almac Clinical Technologies continues to be the premier partner for the implementation of complex innovative trial designs. In FY24 Almac Clinical Technologies invested in its biostats department and launched new biostatistical services to support these trials. Almac Clinical Technologies is now involved in partnering with Clinical Trial Protocol writers to help design their trials when complex innovative designs will support their study goals. In addition to this, a randomization monitoring service has been introduced to meet emerging regulatory guidelines in these trials.</li> </ul>
------------------------------------	--

# The McClay Foundation

## (a company limited by guarantee)

### Trustees' report for the year ended 30 September 2024 (incorporating the Directors' report) (continued)

<p>Almac Group (continued)</p>	<p>In the last 12 months Almac has maintained 112 granted patents with a further 70 pending approval. These include the following:</p> <ul style="list-style-type: none"> <li>○ Almac Discovery – DUB inhibitors (including USP19), Protein Drug Conjugates (including ROR1), PNU Payloads and Loop Library Variants.</li> <li>○ Almac Diagnostics – DDRD assay (prostate cancer)</li> </ul> <p>Almac continues to collaborate with academia and other global institutions to deepen its existing knowledge and skills in specific areas. Utilising the additional resource, data, and insight available through these partnerships enables Almac to continue to deliver Group wide innovation and progress its R&amp;D activity effectively. Examples include the following:</p> <ul style="list-style-type: none"> <li>○ Helmholtz Research Centre Munich (DUB inhibitors)</li> <li>○ Elasmogen/Aberdeen University (ROR-1 cell surface receptor)</li> <li>○ S-CORT (Oxford University &amp; others - DDRD Assay/Colorectal cancer)</li> </ul>
--------------------------------	--

## 2. Oncology Research – Targets and Biomarkers

### Strategic Aims

1. To create and sustain a world class research infrastructure and culture in Northern Ireland to advance current research practice and procedures in oncology globally.
2. To choose and appoint leaders with academic/industrial experience to inspire and drive relevant and meaningful research.
3. To develop novel and strategic approaches to personalised cancer treatment with greater potential benefits overall.

### Activities and Impact

<p>QUB - £154,736</p>	<p>Professors Richard Kennedy and Tim Harrison continued their research in their capacities as McClay Chair in Medical Oncology and Medicinal Chemistry respectively at Queen's University Belfast ("QUB").</p> <p><b><u>Professor Tim Harrison - McClay Chair in Medicinal Chemistry</u></b></p> <p><b>Research</b></p> <p>Working with Prof. Dan Longley and Ipsen Pharma on development of First in Class FLIP inhibitors following out-licensing of this QUB derived programme to Ipsen in November 2022. There is the potential for these first in class inhibitors to provide new and improved treatment options for cancer patients, which aligns with The McClay Foundation's objectives. Based on the biology of FLIP, following clinical proof of concept in cancer patients, the compounds may also have further utility in indications beyond cancer. Joint supervisor for a Post Doctoral Research Associate as part of a cross-border Higher Education Authority-funded North-South Research Project joint with Trinity College, Dublin evaluating new activity probes for deubiquitinase enzymes. One aim of this programme is to provide a catalyst for All-Island Collaboration in Research Excellence. A publication has been submitted based on this work. Professor Harrison was lead author of a publication in the journal <i>Clinical and Translational Medicine</i> in April 2024 entitled "USP7 inhibitors suppress tumour neo angiogenesis and promote synergy with immune checkpoint inhibitors by downregulating fibroblast VEGF". This publication demonstrated for the first time that USP7-mediated reprogramming of the tumour microenvironment represents a function of USP7 that is unique to fibroblasts, and which is not observed in cancer cells. Given the potential for USP7 inhibitors to transform "immune desert" tumors into "immune responsive" tumors, this paves the way for a novel therapeutic strategy combining USP7 inhibitors with immune checkpoint inhibitors (ICIs).</p>
-----------------------	--

# The McClay Foundation

(a company limited by guarantee)

## Trustees' report for the year ended 30 September 2024 (incorporating the Directors' report) (continued)

<p>QUB - £154,736 (continued)</p>	<p><b>Publications</b></p> <p>Author or inventor on &gt;145 publications, patents and patent applications. Most recently:</p> <p><b><u>Jurisc, A <i>et al.</i> USP7 inhibitors suppress tumour neoangiogenesis and promote synergy with immune checkpoint inhibitors by downregulating fibroblast VEGF <i>Clin. Trans. Med.</i> 2024 Apr;14(4):e1648. doi: 10.1002/ctm2.1648</u></b></p> <p>Page, N.<i>et al.</i> Identification and development of a subtype- selective allosteric AKT inhibitor suitable for clinical development. <i>Sci Rep</i> 12, 15715 (2023). <a href="https://doi.org/10.1038/s41598-022-20208-5">https://doi.org/10.1038/s41598-022-20208-5</a></p> <p><b><u>Hewitt, P. R. et al. Deubiquitinases and their inhibitors: challenges and recent advances</u></b> <i>Medicinal Chemistry Reviews</i> (2022), 57, 363-387</p> <p><b>Talks and Teaching</b></p> <ul style="list-style-type: none"> <li>• <b>Exploiting Engineered Binding Domains in Next Generation Antibody-Drug Conjugate Design</b> – Invited Lecture – 26<sup>th</sup> International Charles Heidelberger Symposium on Cancer Research – Oct 2024</li> <li>• <b>Translational Research: from Concept to Commercialisation (MRES) Teaching</b>, QUB, October 2024 – Lecture: The Drug Discovery and Development Process</li> <li>• <b>Careers Talk, QUB Postgraduate Students</b>, “Careers in the Pharmaceutical Industry”, May 2024</li> </ul> <p><b>Grants:</b></p> <ul style="list-style-type: none"> <li>• Small molecule inhibitors of the anti-apoptotic protein FLIP for the treatment of cancer, Wellcome Trust Seeding Drug Discovery Award, 2015, £5,600,000 – 4-year programme independent of Almac (co-PI)</li> <li>• June 2019 - Centre of Excellence for Ubiquitin Drug Discovery, £5.1M Invest Northern Ireland grant (PI).</li> <li>• BREATH<sup>7</sup> (Border and Regions Airways Training Hub) Post-Doctorate Researcher / Research Fellow has funded under the European Union’s INTERREG VA Programme (ca. £100K, PI)</li> <li>• Innovation Scholar – IUK funded: working with Prof. Dan Longley</li> <li>• Innovation Scholar – IUK funded: working with Dr James Reihill</li> <li>• Joint Supervisor (with Joanna McGouran, Trinity College, Dublin) for 2 year HEA Funded North South Project: “Snapshot: Target engagement assays – a radical approach to capture a snapshot of probe-enzyme binding” – €200K</li> <li>• Co-Applicant for NI Strength in Places bid: “Future Medicines Institute” (£34.5M programme, pending)</li> <li>• Co-PI for BBSRC funded “Prosperity Partnership” grant: “Establishment of a NI Centre of Excellence for Proteomics” (£5.2M programme)</li> </ul>
---------------------------------------	---

# The McClay Foundation

(a company limited by guarantee)

## Trustees' report for the year ended 30 September 2024 (incorporating the Directors' report) (continued)

<p><b>QUB - £154,736</b> (continued)</p>	<p>Panel membership:</p> <ul style="list-style-type: none"> <li>• Panel member – Medical Research Council (MRC) Developmental Pathway Funding Scheme (DPFS)</li> <li>• Panel member – British Heart Foundation (BHF), Translational Awards Committee</li> <li>• Panel member: QUB Research Innovation and Translation Committee</li> <li>• Chair – QUB MRC Funder Liaison Group</li> </ul> <p>PhD Supervisor for 4 PhD Students</p> <ul style="list-style-type: none"> <li>• TACT Marie Curie ETN – Joint PhD supervisor for Thomas Favraud, 3-year programme (with G Cotton)</li> <li>• Joint PhD Supervisor (with Simon McDade) for Mark Wappett: Mark is undertaking a PhD by publication in bioinformatics. This is a first of its kind at QUB and will provide a blueprint for others who want to follow this route.</li> <li>• PhD Supervisor for Lauren Proctor: Lauren is undertaking a part time PhD in medicinal chemistry at QUB whilst working at Almac Discovery</li> <li>• PhD Supervisor for Patrick Preston (joint with K Savage) – DfE funded 3-year studentship “Understanding the role of ubiquitination on STING-mediated immune regulation following DNA damage”</li> </ul> <p><b><u>Professor Richard Kennedy - McClay Chair in Medical Oncology</u></b></p> <p>Co-principal investigator for the Precision Medicine Group at Queen’s University Belfast, focussing on Biomarkers and drug targets to guide precision medicine. Our main area of interest is to better understand the immune system and how it recognises cancer. This may allow us to develop new drug therapies that allow a patient’s immune system to identify and eradicate cancer.</p> <p><b>Publications</b></p> <ol style="list-style-type: none"> <li>1. USP7 inhibitors suppress tumour neoangiogenesis and promote synergy with immune checkpoint inhibitors by downregulating fibroblast VEGF. Clin Transl Med. 2024 Apr;14(4)</li> <li>2. Integrated multimodal analyses of DNA damage response and immune markers as predictors of response in metastatic triple-negative breast cancer in the TNT trial (NCT00532727). Clinical Cancer Research, Vol. 29, No. 18, 15.09.2023</li> <li>3. An investigation of the clinical impact and therapeutic relevance of a DNA damage immune response (DDIR) signature in patients with advanced gastroesophageal adenocarcinoma. ESMO Open, Vol. 9, No. 5, 103450, 13.05.2024</li> <li>4. Ruthenium drug BOLD-100 regulates BRAFMT colorectal cancer cell apoptosis through AhR/ROS/ATR signaling axis modulation. Molecular Cancer Research, 04.09.2024.</li> <li>5. Dual prognostic classification of triple-negative breast cancer by DNA damage immune response and homologous recombination deficiency. JCO Precision Oncology 2023. 7, e2300197</li> <li>6. STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway. Molecular Cancer 2023. 22, 1, 133.</li> <li>7. MCU Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727). Clin Cancer Res. 2023 Sep 15;29(18):3691-3705.</li> </ol> <p><b>Presentations</b></p> <ul style="list-style-type: none"> <li>• “Biomarker Discovery and Development” Cancer Research Horizons Biomarker Commercialization Summit, Manchester University Nov 2023</li> <li>• “20 years of Clinical Biomarker Development” 26th International Charles Heidelberger Symposium on Cancer Research Oct 2024</li> </ul>
--	--

# The McClay Foundation

(a company limited by guarantee)

## Trustees' report for the year ended 30 September 2024 (incorporating the Directors' report) (continued)

<p><b>QUB - £154,736</b> (continued)</p>	<p><b>Awarded Grants:</b></p> <ul style="list-style-type: none"> <li>- Future Medicines Institute- Innovate UK- Co-PI- £31 Million Oct 2024</li> <li>- Development of Glycoprotein targeted drugs- Aviceda Co-PI- £546,000 Nov 2023</li> <li>- Characterization of DNA Damaging Drug Immune activation in Ovarian Cancer- Grand Lodge of Freemasons Co-PI- £70,318 Feb 2024</li> </ul> <p><b>Teaching</b></p> <ul style="list-style-type: none"> <li>- MED2016 Masters course lecturer</li> <li>- MRES SCM7075 Masters course lecturer</li> <li>- PhD supervisor 2 students</li> <li>- Supervision 1 MSc Student QUB</li> <li>- Supervision 1 MSc Student Royal College of Surgeons Dublin</li> <li>- Faculty Mentor for lecturers: Dr Bob Ladner, Dr Yaser Atlasi, Dr Aiden Cole, Dr Sandra Van Shaebroek and Dr Emma Kerr</li> </ul> <p><b>Outreach Activities/ Panel Memberships</b></p> <ul style="list-style-type: none"> <li>• Member of MATRIX committee, Scientific advisory board to NI Government.</li> <li>• Chair of Research Committee commissioned by Dept of Economy to establish NI Life and Health Sciences Ecosystem around City and Regional Growth Deals. Published May 2024 and recommendations formally adopted by Minister Murphy into NI Economic Policy.</li> <li>• Member of the Health Innovation Research Alliance Northern Ireland Health Leaders Committee</li> <li>• Member of the Faculty of Pharmaceutical Medicine Oncology Advisory Board</li> <li>• Director of OML (Odyssey Belfast): A charity that manages the SSE Arena, Belfast, W5 and the Odyssey site to support wellbeing and better life chances for the people of Northern Ireland</li> </ul>
--	--

# The McClay Foundation

## (a company limited by guarantee)

### Trustees' report for the year ended 30 September 2024 (incorporating the Directors' report) (continued)

#### 3. Dignity and Compassion - Research Led Care for Those in End of Life or Life Limited Circumstances

##### Strategic Aims

1. To ensure everyone has access to good quality end of life care, regardless of their circumstances, age, disease, or culture and wherever their place of care.
2. To provide quality of life, positive outcomes, and experiences to those in end-of-life care.
3. To provide care and support for life limited children, currently identified as being severely lacking in Northern Ireland.
4. To support those organisations who provide holistic care, meeting people's physical, emotional, social, psychological, and spiritual needs, in end of life and life limited circumstances.

##### Activities and Impact

Buddy Bear Trust £100,000	Partnering with the Buddy Bear Trust School in Dungannon which provides conductive education and support for children suffering from cerebral palsy and other motor disorders in support of its Lifetime of Difference (phase 2) project.
Cancer Fund for Children £50,000	The Foundation continues to provide support towards the running costs of Cancer Fund for Children's residential centre, Daisy Lodge, in Newcastle.
NI Hospice £50,000	Supporting Northern Ireland Hospice as it employs nurses to provide palliative care to patients in their own homes as part of the hospice's high-quality, holistic end-of-life care which enables patients to have the appropriate support to remain at home as they approach the end of life.
Action Cancer Northern Ireland £50,000	Contributed towards the costs of two machines used by Action Cancer for digital breast tomosynthesis screening as part of its breast cancer screening programme. One machine is located at Action Cancer House and the other is located on Action Cancer's Big Bus.
Friends of the Cancer Centre £70,000	Supporting Friends of the Cancer Centre to fund an additional clinical nurse specialist and also supporting its financial grant programme which seeks to mitigate some of the potential financial impacts on patients receiving cancer treatment.
Young Lives v Cancer £25,000	Contributing funding towards Young Lives v Cancer's 'Home from Home' project which offers accommodation for parents and siblings close to Belfast City Hospital and the Royal Belfast Hospital for Sick Children, helping to alleviate the additional financial burdens of travel, accommodation and food costs often experienced by families when a young person is receiving cancer treatment.

# The McClay Foundation

## (a company limited by guarantee)

### Trustees' report for the year ended 30 September 2024 (incorporating the Directors' report) (continued)

#### 4. To Promote Health & Wellbeing in Disenfranchised Communities & Geographical Areas

##### Strategic Aims

1. To provide holistic community-based healthcare, empowerment, wellbeing, and education to disenfranchised communities, whether in the developed or developing world.
2. To foster effective partnerships and collaborate with NGOs who are providing individuals with healthcare services and education in disenfranchised communities on a 'better together' basis.
3. To provide innovative and responsive solutions to specific health and wellbeing issues in the developing world.
4. To provide assistance and support to achieve long lasting and significant improvement in the health and wellbeing of those living in poverty.

##### Activities and Impact

Fields of Life £125,000	Supporting Fields of Life's I AM GIRL initiative, which aims to empower girls in East Africa to complete their education and to grow into strong, healthy young women. By constructing hygienic washroom facilities at schools, supporting school feeding programmes to encourage school retention, and providing training on child protection and gender equality, I AM GIRL seeks to reduce the barriers to adolescent girls' and other children's participation in education in schools and communities in East Africa.  Supporting Fields of Life's vocational training institute scholarships to enable vulnerable young people to study courses such as building construction; carpentry; tailoring, fashion and design; and cosmetology, hair and beauty. The young people supported by these scholarships have the opportunity to learn skills which enable them to secure jobs, earn a living and have the prospect of a brighter future.
Philadelphia Education Fund £11,172	Scholarship to assist selected student over the term of their studies. The student was chosen from underrepresented communities in the Philadelphia Area.
Train To Be Smart £37,720	Supporting Train 2B Smart in Northern Ireland which seeks to promote the improvement of mental health and wellbeing through sport. The Foundation has provided particular support for Train 2B Smart's project co-ordinator role and its "#itssmarttotalk' campaign.
Leprosy Mission NI, £8,386	The Foundation has provided support for a self-help group run by the Leprosy Mission in Bangladesh. Through screening, the provision of vital medical care and enhancing community inclusion and mental health, the Leprosy Mission's project seeks to detect, treat and prevent leprosy.
Reach Mentoring, £15,670	Reach Mentoring partners with local schools to provide one-to-one mentoring support for children and young people. The Foundation has provided support towards the costs of Reach's Mentoring Coordinator.
Children in Northern Ireland £55,000	Supporting Children in Northern Ireland (CiNI) in its 'Holiday Hunger' and 'Get Active' Programmes which aim to engage children and young people, ordinarily in receipt of free school meals, during holiday periods. CiNI's programmes seek to address issues faced by young people including food poverty, educational underachievement and health and wellness through the provision of nutritious meals, physical activity sessions and learning-based activities.
Friends of Parkview Special School £2,750	Assisted Friends of Parkview Special Needs School in Lisburn, Northern Ireland with its recent summer activity scheme.
Friends of Parkview Special School £4,650	Covered the costs of 6 mobility bicycles to be used by the children and young people at Friends of Parkview Special Needs School.

# The McClay Foundation

## (a company limited by guarantee)

### Trustees' report for the year ended 30 September 2024 (incorporating the Directors' report) (continued)

#### Public benefit assessment

For each Strategic Focus Area, we will identify and monitor on an ongoing basis:

- The beneficiaries and the effect of our engagement.
- The purpose of our engagement.
- The direct benefits which flow from our chosen purpose.
- How the benefits are (or will be) demonstrated.
- How the engagement / benefits fulfil the Foundation's charitable purposes.

#### Monitoring

- To record the basis of support for any Project.
- To make clear, as part of that support, the expectations of the Foundation.
- To set goals as to reporting against outputs.
- To receive Project updates and carry out inspections.
- To learn from experience and maximise future support in achieving public benefit and the Foundation's goals.

Beneficiaries are required to report to the Foundation on an interim basis and at the end of their applicable funding period. Such reports typically summarise the activities undertaken and include details of the end-users who have benefitted from the activities/projects. In addition, testimonials from beneficiaries also indicate the difference which the Foundation's grant-making activities have had on both individual beneficiaries and at a societal level.

#### Public benefit statement

The public benefit requirement is defined in the Charities Act (Northern Ireland) 2008 and states that purposes must be for the public benefit to be charitable. The Trustees confirm that they have complied with the duty to have regard to the guidance issued by the Charity Commission for Northern Ireland under section 4(b) of the Charities Act (the public benefit requirement statutory guidance). The Trustees are confident that the activities have helped to achieve the Charity's purposes and provide a benefit to the beneficiaries.

#### Financial review

During the year donations of £750,000 (2023: £500,000) were received from subsidiaries of Almac Group, and direct charitable expenditure of £760,084 (2023: £637,668) was incurred by the charity, as disclosed in note 5. Net outgoing resources for the year amounted to £780,825 (2023: £650,075). The charitable company's net assets are £91,042,082 (2023: £91,033,578).

The Trustees are satisfied that the outcome is in line with the charity's planned expenditure on projects which they have decided to fund over a period of several years to enable the aims of each project within each strategic focus area to be achieved. The Trustees are considering future funding requirements on an ongoing basis.

#### Reserves policy

The Trustees have established a policy whereby the free reserves held by the charity should match its needs, both at the current time and in the foreseeable future. After making allowances for restricted funds, designated funds, and the carrying amount of functional assets, the charity had free reserves of £532,082 (2023: £523,578) which represents 8 months of expenditure. The free reserves required will be sufficient to meet the running costs for a period equivalent to 6-9 months of expenditure. This policy is reviewed annually. The Board of Trustees will continue to monitor the reserves position and movement in reserves in line with the policy to ensure there is no immediate risk.

# **The McClay Foundation**

## **(a company limited by guarantee)**

### **Trustees' report for the year ended 30 September 2024 (incorporating the Directors' report) (continued)**

#### **Investment policy**

The Trustees have the power to invest in such assets as they see fit, subject to the charity's Articles of Association. Proposed investments must be tabled for review and approval at a meeting of the board of Trustees.

#### **Taxation status**

The McClay Foundation is a registered charity, and as such is entitled to certain tax exemptions on income and profits from investments, and surpluses on any trading activities carried on in furtherance of the charity's primary objectives, if these profits and surpluses are applied solely for charitable purposes.

The charity is not registered for VAT and accordingly, all its expenditure is recorded inclusive of any VAT incurred.

#### **Plans for future periods**

The Trustees' plans for the future are focused on delivering the charitable obligations which are detailed in the Foundation's chosen Strategic Focus areas. The Trustees have decided to fund chosen projects for an appropriate number of years to allow the maximum degree of planning and implementation for such projects to enable them to achieve the most beneficial impact.

#### **Going concern**

The trustees have received confirmation that Almac Group Limited intends to support the company for at least one year after these financial statements are signed. Consequently, the trustees have prepared these financial statements on a going concern basis.

#### **Funds held as custodian trustee on behalf of others**

There are no funds held as custodian trustee on behalf of others.

#### **Statement of Trustees' responsibilities**

The Trustees (who are also directors of The McClay Foundation for the purposes of company law) are responsible for preparing the Trustees' Annual Report and the financial statements in accordance with applicable law and regulation.

Company law requires the Trustees to prepare financial statements for each financial year. Under that law the Trustees have prepared the financial statements in accordance with United Kingdom Accounting Standards, comprising FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", and applicable law (United Kingdom Generally Accepted Accounting Practice). Under company law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of the affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Statement of Recommended Practice: Accounting and Reporting by Charities (2019);
- make judgments and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards, comprising FRS 102, have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charitable company's transactions and disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

# **The McClay Foundation**

**(a company limited by guarantee)**

## **Trustees' report for the year ended 30 September 2024 (incorporating the Directors' report) (continued)**

### **Statement of disclosure of information to auditors**

So far as each of the Trustees in office at the date of approval of these financial statements is aware:

- there is no relevant audit information of which the charitable company's auditors is unaware; and
- they have taken all the steps that they ought to have taken as Trustees in order to make themselves aware of any relevant audit information and to establish that the charitable company's auditors are aware of that information.

### **Small companies' exemption**

This report has been prepared in accordance with the special provisions relating to small companies within Part 15 of the Companies Act 2006.

### **Independent auditors**

The auditors, PricewaterhouseCoopers (Northern Ireland) LLP, have indicated their willingness to continue in office, and a resolution concerning their reappointment will be proposed at the Annual General Meeting.

This report was approved by the board of Trustees and signed on its behalf.



A D Armstrong  
Trustee

27 February 2025

# The McClay Foundation (a company limited by guarantee)

## *Independent auditors' report to the members of The McClay Foundation*

### Report on the audit of the financial statements

---

#### **Opinion**

In our opinion, The McClay Foundation's financial statements (the "financial statements"):

- give a true and fair view of the state of the charitable company's affairs as at 30 September 2024 and of its incoming resources and application of resources, including its income and expenditure, and cash flows, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards, including FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", and applicable law); and
- have been prepared in accordance with the requirements of the Companies Act 2006.

We have audited the financial statements, included within the Annual Report and Financial Statements (the "Annual Report"), which comprise: the balance sheet as at 30 September 2024; the statement of financial activities (incorporating an income and expenditure account and the cash flow statement for the year then ended; and the notes to the financial statements, which include a description of significant accounting policies

---

#### **Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (UK) ("ISAs (UK)") and applicable law. Our responsibilities under ISAs (UK) are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### **Independence**

We remained independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, which includes the FRC's Ethical Standard and we have fulfilled our other ethical responsibilities in accordance with these requirements.

---

#### **Conclusions relating to going concern**

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from the date on which the financial statements are authorised for issue.

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

However, because not all future events or conditions can be predicted, this conclusion is not a guarantee as to the charitable company's ability to continue as a going concern.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

---

#### **Reporting on other information**

The other information comprises all of the information in the Annual Report other than the financial statements and our auditors' report thereon. The trustees are responsible for the other information. Our opinion on the financial statements does not cover the other information and, accordingly, we do not express an audit opinion or, except to the extent otherwise explicitly stated in this report, any form of assurance thereon.

# **The McClay Foundation** **(a company limited by guarantee)**

## ***Independent auditors' report to the members of The McClay Foundation (continued)***

### **Reporting on other information (continued)**

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If we identify an apparent material inconsistency or material misstatement, we are required to perform procedures to conclude whether there is a material misstatement of the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report based on these responsibilities.

With respect to the Trustees' report, we also considered whether the disclosures required by the UK Companies Act 2006 and Charities Act (Northern Ireland) 2008 have been included.

Based on our work undertaken in the course of the audit, the Companies Act 2006 requires us also to report certain opinions and matters as described below.

#### ***Trustees' report***

In our opinion, based on the work undertaken in the course of the audit the information given in the Trustees' report for the period ended 30 September 2024 is consistent with the financial statements and has been prepared in accordance with applicable legal requirements.

In light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we did not identify any material misstatements in the Trustees' report.

---

### **Responsibilities for the financial statements and the audit**

#### ***Responsibilities of the trustees for the financial statements***

As explained more fully in the Statement of Trustees' Responsibilities, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements in accordance with the applicable framework and for being satisfied that they give a true and fair view. The trustees are also responsible for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

#### ***Auditors' responsibilities for the audit of the financial statements***

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

# The McClay Foundation (a company limited by guarantee)

## *Independent auditors' report to the members of The McClay Foundation (continued)*

### **Responsibilities for the financial statements and the audit (continued)**

#### *Auditors' responsibilities for the audit of the financial statements (continued)*

Based on our understanding of the charitable company and its environment, we identified that the principal risks of non-compliance with laws and regulations related to Charities Act (Northern Ireland) 2008, and we considered the extent to which non-compliance might have a material effect on the financial statements. We also considered those laws and regulations that have a direct impact on the financial statements such as the Companies Act 2006. We evaluated management's incentives and opportunities for fraudulent manipulation of the financial statements (including the risk of override of controls) and determined that the principal risks were related to the posting of inappropriate journal entries. Audit procedures performed by the engagement team included:

- Enquiry of management and the board of trustees, including consideration of known or suspected instances of non-compliance with laws and regulations and fraud;
- Reading minutes of meetings of the board of trustees;
- Understanding and evaluating the charitable company's control environment;
- Identifying and testing journal entries; including journal entries posted with unusual account combinations to income or expenditure accounts;
- Assessing financial statement disclosures, and testing to supporting documentation, for compliance with applicable laws and regulations.

There are inherent limitations in the audit procedures described above. We are less likely to become aware of instances of non-compliance with laws and regulations that are not closely related to events and transactions reflected in financial statements. Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations or through collusion.

A further description of our responsibilities for the audit of the financial statements is located on the FRC's website at: [www.frc.org.uk/auditorsresponsibilities](http://www.frc.org.uk/auditorsresponsibilities). This description forms part of our auditors' report.

#### *Use of this report*

This report, including the opinions, has been prepared for and only for the charitable company's members as a body in accordance with Chapter 3 of Part 16 of the Companies Act 2006 and for no other purpose. We do not, in giving these opinions, accept or assume responsibility for any other purpose or to any other person to whom this report is shown or into whose hands it may come save where expressly agreed by our prior consent in writing.

---

## **Other required reporting**

### **Companies Act 2006 exception reporting**

Under the Companies Act 2006 we are required to report to you if, in our opinion:

- we have not obtained all the information and explanations we require for our audit; or
- adequate accounting records have not been kept by the charitable company, or returns adequate for our audit have not been received from branches not visited by us; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- the charitable company financial statements are not in agreement with the accounting records and returns.

We have no exceptions to report arising from this responsibility.


**The McClay Foundation  
(a company limited by guarantee)**

***Independent auditors' report to the members of The  
McClay Foundation (continued)***

**Other required reporting (continued)**

**Entitlement to exemptions**

Under the Companies Act 2006 we are required to report to you if, in our opinion, the trustees were not entitled to: prepare financial statements in accordance with the small companies' regime; take advantage of the small companies' exemption in preparing the Trustees' report; and take advantage of the small companies exemption from preparing a Strategic Report. We have no exceptions to report arising from this responsibility.



Emma Murray (Senior Statutory Auditor)  
for and on behalf of PricewaterhouseCoopers (Northern Ireland) LLP  
Chartered Accountants and Statutory Auditors  
Belfast  
27 February 2025

# The McClay Foundation

(a company limited by guarantee)

## Statement of financial activities (incorporating income and expenditure account) for the year ended 30 September 2024

	Note	Total unrestricted funds 2024 £	Total unrestricted funds 2023 £
<b>Incoming resources from generated funds</b>			
Investment income	4	22,094	16,526
Donations	4	767,235	500,000
<b>Total incoming resources</b>	4	<b>789,329</b>	<b>516,526</b>
<b>Resources expended</b>			
Charitable activities	5	(760,084)	(637,668)
Governance costs	5	(20,741)	(12,407)
<b>Total resources expended</b>		<b>(780,825)</b>	<b>(650,075)</b>
<b>Net income/(expenditure) and net movement in funds before gains and losses on investments</b>		<b>8,504</b>	<b>(133,549)</b>
Net gains on investment property assets	10	-	-
<b>Net income/(expenditure) and net movement in funds</b>		<b>8,504</b>	<b>(133,549)</b>
<b>Total funds brought forward at 1 October</b>		<b>91,033,578</b>	<b>91,167,127</b>
<b>Total funds carried forward at 30 September</b>		<b>91,042,082</b>	<b>91,033,578</b>

The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.


# The McClay Foundation

(a company limited by guarantee)

## Balance sheet as at 30 September 2024

	Note	2024 £	2023 £
<b>Fixed assets</b>			
Investments	9	90,300,000	90,300,000
Investment property	10	210,000	210,000
		<b>90,510,000</b>	<b>90,510,000</b>
<b>Current assets</b>			
Debtors: amounts falling due within one year	11	910	870
Cash at bank and in hand		591,801	580,238
		<b>592,711</b>	<b>581,108</b>
<b>Creditors: amounts falling due within one year</b>	12	<b>(60,629)</b>	<b>(57,530)</b>
<b>Net current assets</b>		<b>532,082</b>	<b>523,578</b>
<b>Net assets</b>		<b>91,042,082</b>	<b>91,033,578</b>
<b>The funds of the charity:</b>			
Unrestricted funds	15	91,042,082	91,033,578
<b>Total charity funds</b>		<b>91,042,082</b>	<b>91,033,578</b>

The financial statements on pages 20 to 31 were approved by the board of Trustees on *27 February 2025* and were signed on its behalf by:

  
A D Armstrong  
Trustee

I W Huddleston  
Trustee



The notes on pages 23 to 31 are an integral part of the financial statements.

# The McClay Foundation

(a company limited by guarantee)

## Cash flow statement for the year ended 30 September 2024

	Note	2024 £	2023 £
<b>Cash flows from operating activities</b>			
Net cash generated from/ (used in) operating activities	14	11,563	(133,821)
<b>Net decrease in cash and cash equivalents</b>			
Cash and cash equivalents at beginning of the year		580,238	714,059
<b>Cash and cash equivalents at end of the year</b>		<b>591,801</b>	<b>580,238</b>

The notes on pages 23 to 31 are an integral part of the financial statements.

# The McClay Foundation

## (a company limited by guarantee)

### Notes to the financial statements for the year ended 30 September 2024

#### 1 Accounting policies

##### General information

The nature of The McClay Foundation is that of a charity. The Foundations objectives are, broadly to:

- Support and encourage research and innovation
- Advance the use of diagnostic tools and drugs in the prevention, control and cure of disease
- Ensure latest advances in healthcare available to all, including developing countries
- Generate and promote employment opportunities
- Support and promote such educational purposes as the trustees shall select, provided that such purposes shall be exclusively charitable in law

The charity is incorporated in the United Kingdom and is registered in Northern Ireland. The address of its registered office is Almac House, 20 Seagoe Industrial Estate, Craigavon, BT63 5QD.

##### Statement of compliance

The individual financial statements of The McClay Foundation have been prepared in compliance with Accounting and Reporting by Charities: Statement of Recommended Practice (SORP), United Kingdom Accounting Standards including Financial Reporting Standard 102, the Companies Act 2006 and the Charities Act (Northern Ireland) 2008.

##### Basis of preparation

The financial statements have been prepared on a going concern basis, under the historic cost convention, and in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice (SORP) applicable to charities preparing their financial statements in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) effective 1 January 2015), (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), the Charities Act (Northern Ireland) 2008 and the Companies Act 2006.

The preparation of the financial statements requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the group and charity accounting policies. Management has concluded that there are no critical assumptions, estimates or judgements involving a high degree of judgement or complexity which require further disclosure as outlined in note 2.

The principal accounting policies, which have been applied consistently throughout the year, are set out below.

##### Consolidation

The McClay Foundation owns 99% of the Ordinary A share capital and 100% of the Ordinary B share capital of Almac Group Limited. The share capital structure of Almac Group Limited also includes a £1 founder share which has veto rights in a number of areas. Under charity law, the Foundation is regarded as the controller of Almac Group Limited which, as a subsidiary of the Foundation, delivers the Foundation's charitable purposes. Although the Foundation is the beneficial owner of Almac Group Limited, the Trustees do not exercise control for the purpose of Section 401 of the Companies Act 2006. The financial statements therefore present information about the company as an individual undertaking.

##### Investments

Investments in associates are held as non current assets and are held at cost less accumulated impairment losses. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount.

##### Investment property

Investment property for which fair value can be measured reliably is measured at fair value annually with any change recognised in the statement of financial activities.

##### Debtors

Debtors are initially stated at cost and subsequently stated after all known bad debts have been written off and specific provision has been made against all debts considered doubtful of collection.

# **The McClay Foundation**

## **(a company limited by guarantee)**

### **Notes to the financial statements for the year ended 30 September 2024 (continued)**

#### **1 Accounting policies (continued)**

##### **Incoming resources**

All incoming resources consist of voluntary income and investment income and are included in the statement of financial activities when the charity is legally entitled to the income and the amount can be quantified with reasonable accuracy.

##### **Donations**

Voluntary income is income which is received by way of donations and gifts to the charity and is included in full in the statement of financial activities when received.

##### **Investment income**

Bank interest and loan interest receivable is included in full in the statement of financial activities on an accruals basis.

##### **Rental income**

Rental income is included in full in the statement of financial activities on an accruals basis.

##### **Policy for the awarding of grants**

The Foundation's grant programs are approved by Trustees. The Foundation will only accept applications from registered charities. All programs involve an application process. Applications are assessed by the Trustees, including robust assessment of governance. Final approval is sought at board meetings, before decisions are shared with applicants. The applicant's must sign up to The Foundation Grant Terms & Conditions before funding is released via bacs payment. All grantees must complete an evaluation report, outlining expenditure, performance, and impact on at least an annual basis.

##### **Resources expended**

Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category. Expenditure relates to charitable activities and governance costs which are outlined below.

##### **Charitable activities**

Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities and services for its beneficiaries. These include oncology research, research led care for those in end of life or life limiting activities and activities to promote health and wellbeing in disenfranchised communities and geographical areas in the developed and the developing world. Charitable activities are both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to supply them.

##### **Governance costs**

Governance costs are costs associated with general charity advice and governance matters and include those costs incurred in the governance of its assets which are associated with constitutional and statutory requirements.

##### **Unrestricted funds**

Unrestricted funds are donations and other incoming resources received or generated which are expendable at the discretion of the charity in furtherance of its objectives.

##### **Cash and cash equivalents**

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term highly liquid investments with original maturities of three months or less and bank overdrafts. Bank overdrafts, when applicable, are shown within borrowings in current liabilities. Deposits with original maturities of greater than 3 months are shown as current asset or fixed asset investments depending on the date of maturity.

# The McClay Foundation

## (a company limited by guarantee)

### Notes to the financial statements for the year ended 30 September 2024 (continued)

#### 1 Accounting policies (continued)

##### Financial instruments

A financial instrument is any contract that gives rise to a financial asset of one party and a financial liability or equity instrument of another party. The charity has chosen to adopt Sections 11 and 12 of FRS 102 in respect of financial instruments which sets out the requirements for the recognition, derecognition, measurement and disclosure of financial assets and financial liabilities

##### Financial assets

Financial assets, including trade and other debtors and cash and bank balances, are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

Such assets are subsequently carried at amortised cost using the effective interest method.

At the end of each reporting period financial assets measured at amortised cost are assessed for objective evidence of impairment. If an asset is impaired the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset's original effective interest rate. The impairment loss is recognised in the Statement of financial activities.

If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been had the impairment not previously been recognised. The impairment reversal is recognised in the Statement of financial activities.

Other financial assets, including investments in equity instruments which are not subsidiaries, associates, or joint ventures, are initially measured at fair value. The quoted market value is used to determine fair value.

Such assets are subsequently carried at fair value and the changes in fair value are recognised in profit or loss, except that investments in equity instruments that are not publicly traded and whose fair values cannot be measured reliably are measured at cost less impairment.

Financial assets are derecognised when (i) the contractual rights to the cash flows from the asset expire or are settled, or (ii) substantially all the risks and rewards of the ownership of the asset are transferred to another party, or (iii) control of the asset has been transferred to another party who has the practical ability to unilaterally sell the asset to an unrelated third party without imposing additional restrictions.

##### Financial liabilities

Financial liabilities, including trade and other creditors, bank overdrafts and other loans, are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future receipts discounted at a market rate of interest.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Trade creditors are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Financial liabilities are derecognised when the liability is extinguished, that is when the contractual obligation is discharged, cancelled, or expires.

# The McClay Foundation

## (a company limited by guarantee)

### Notes to the financial statements for the year ended 30 September 2024 (continued)

#### 2 Critical accounting judgements and estimation uncertainty

Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations on future events that are believed to be reasonable under the circumstances.

*(a) Critical judgements in applying the company's accounting policies*

There are no critical judgements in applying the company's accounting policies

*(b) Critical accounting estimates and assumptions*

There are no critical accounting estimates and assumptions.

#### 3 Legal status of the charity

The charity is a company limited by guarantee and has no share capital. The liability of each member in the event of winding-up is limited to £1.

#### 4 Total incoming resources

	Total unrestricted funds 2024 £	Total unrestricted funds 2023 £
<b>Investment income</b>		
Bank interest	14,294	8,726
Rental income	7,800	7,800
<b>Total investment income</b>	<b>22,094</b>	<b>16,526</b>
<b>Donations</b>		
Donations from Almac Group	750,000	500,000
Donations - other	17,235	-
<b>Total donations</b>	<b>767,235</b>	<b>500,000</b>
<b>Total incoming resources</b>	<b>789,329</b>	<b>516,526</b>

# The McClay Foundation

(a company limited by guarantee)

## Notes to the financial statements for the year ended 30 September 2024 (continued)

### 5 Charitable activities

	Total unrestricted funds 2024 £	Total unrestricted funds 2023 £
Queen's University Belfast	154,736	151,040
Action Cancer Northern Ireland	50,000	-
Northern Ireland Hospice	50,000	100,000
NI Cancer Fund for Children	50,000	-
Friends of the Cancer Centre	70,000	70,000
Get Active	-	25,000
Quest Malawi	-	100,500
Fields of Life	125,000	-
Young Lives v Cancer	25,000	25,000
Leprosy Mission NI	8,386	-
Train to be Smart	37,720	37,720
Reach Mentoring	15,670	-
Philadelphia Education Fund	11,172	15,658
Cope Children's Trust	-	10,000
Buddy Bear Trust	100,000	100,000
Children in Northern Ireland	55,000	-
Friends of Parkview Special School	7,400	2,750
	<b>760,084</b>	<b>637,668</b>

Charitable activities comprise those costs incurred by the charity in the delivery of its activities and services for its beneficiaries. Includes oncology research, research led care for those in end of life or life limiting activities and activities to promote health and wellbeing in disenfranchised communities and geographical areas in the developed and the developing world.

Governance costs in relation to professional services in the year were £20,741 (2023: £12,407).

# The McClay Foundation

## (a company limited by guarantee)

### Notes to the financial statements for the year ended 30 September 2024 (continued)

#### 6 Movement in funds

	2024	2023
	£	£
<b>The net movement in funds are stated after charging:</b>		
Fees payable to the charitable company's auditors for the audit of the financial statements	10,264	6,149

#### 7 Employee information

To date there have been no staff employed by the charitable company and there is no key management to disclose (2023: Nil). The Trustees received no remuneration or reimbursement of expenses in respect of their services. Indemnity insurance is in place for all Trustees and the charge for the year ended 30 September 2024 was £6,000 (2023: £6,000).

#### 8 Taxation

The company is a registered charity and, as such, is entitled to certain tax exemptions on income and profits from investments and surpluses on any trading activities carried on in furtherance of the charitable company's primary objectives, if these profits and surpluses are applied solely for charitable purposes.

#### 9 Investments

	Investment in associate £
At 1 October 2023 and 30 September 2024	90,300,000

During the year ended 30 September 2009, Dr Sir Allen McClay gifted 961,538 'B' ordinary shares in Almac Group Limited to The McClay Foundation.

During the year ending 30 September 2012 the Executors of the estate of Dr Sir Allen McClay gifted 657,327 'B' ordinary shares in Almac Group Limited to The McClay Foundation.

During the year ending 30 September 2014, the trustees of the Allen J. McClay (Almac) Discretionary Settlement gifted 13,286,028 'A' ordinary shares in Almac Group Limited to The McClay Foundation.

During the year ending 30 September 2014, the trustees of The Allen J. McClay Settlement gifted 142,718 'B' ordinary shares in Almac Group Limited to The McClay Foundation.

During the year ending 30 September 2017, the trustees of The Allen J. McClay Settlement gifted 78,207 'A' ordinary shares in Almac Group Limited to The McClay Foundation.

During the year ending 30 September 2018, the trustees of The Allen J. McClay Settlement gifted 8,523 'A' ordinary shares in Almac Group Limited to The McClay Foundation.

During the year ending 30 September 2019, the trustees of The Allen J. McClay Settlement gifted 5,750 'A' ordinary shares in Almac Group Limited to The McClay Foundation.

The total number of "A" ordinary shares now owned is 13,378,508 and the total number of "B" ordinary shares now owned is 1,761,583.

# The McClay Foundation

## (a company limited by guarantee)

### Notes to the financial statements for the year ended 30 September 2024 (continued)

#### 9 Investments (continued)

The charitable company's associated undertaking is:

Name	Country of incorporation	Ownership %	Share Class
<b>Associated undertaking</b>			
Almac Group Limited	Northern Ireland	99%	'A' Ordinary shares of £1 each
		100%	'B' Ordinary shares of £1 each

The principal activities of Almac Group Limited extend from drug discovery through all areas of clinical trials to the commercialisation of pharmaceutical products. The group provides world-class integrated research and development support and an unparalleled range of services to customers, including the market leaders, within the pharmaceutical and biotechnology sectors. The aggregate capital and reserves and results of the company's associated undertaking for the year were:

	2024	2023
	£	£
<b>Capital and reserves</b>		
Almac Group Limited	796,840,991	718,195,917
<b>Profit for the year</b>		
Almac Group Limited	95,910,098	79,950,443

The trustees are satisfied that the carrying value of investments is supported by their underlying net assets.

#### 10 Investment property

	Investment property £
As 1 October 2023 and at 30 September 2024	210,000

During the year ended 30 September 2022 the property was revalued on a fair value basis as at 30 September in accordance with the charities accounting policy by independent external valuers at a value of £210,000. As at 30 September 2024, the trustees performed the valuation and no revaluation was required to be posted.

#### 11 Debtors: amounts falling due within one year

	2024	2023
	£	£
Prepayments	910	870

#### 12 Creditors: amounts falling due within one year

	2024	2023
	£	£
Accruals	60,629	57,530

# The McClay Foundation

(a company limited by guarantee)

## Notes to the financial statements for the year ended 30 September 2024 (continued)

### 13 Financial instruments

	2024	2023
	£	£
<b>Financial liabilities held at amortised cost</b>		
Accruals	60,629	57,530

### 14 Reconciliation of net movement in funds to net cash flow from operating activities

	2024	2023
	£	£
Net movement in funds	8,504	(133,549)
Movement in debtors	(40)	(870)
Movement in creditors	3,099	598
<b>Net cash generated from/ (used in) operating activities</b>	<b>11,563</b>	<b>(133,821)</b>

#### Net funds reconciliation as at 30 September 2024

	Cash at bank and in hand £
As at 1 October 2022	714,059
Cash flows	(133,821)
As at 30 September 2023	580,238
<b>Cash flows</b>	<b>11,563</b>
<b>As at 30 September 2024</b>	<b>591,801</b>

### 15 Unrestricted funds

	Total unrestricted funds 2024 £	Total unrestricted funds 2023 £
At 1 October	91,033,578	91,167,127
Net movement in funds	8,504	(133,549)
<b>At 30 September</b>	<b>91,042,082</b>	<b>91,033,578</b>

# The McClay Foundation

(a company limited by guarantee)

## Notes to the financial statements for the year ended 30 September 2024 (continued)

### 16 Analysis of net assets between funds

	Total unrestricted funds 2024 £	Total unrestricted funds 2023 £
Fixed assets	90,510,000	90,510,000
Net current assets	532,082	523,578
<b>At 30 September</b>	<b>91,042,082</b>	<b>91,033,578</b>

### 17 Ultimate controlling party

The Board of Trustees are the ultimate controlling party.

### 18 Related party transactions

Almac Group Limited is a related party through common directors. Donations of £750,000 (2023: £500,000) were received from subsidiaries of Almac Group during the year.

### 19 Contingent liabilities

At the year end the charity had contingent liabilities of:

	2024 £	2023 £
NI Hospice	150,000	200,000
NI Cancer Fund for Children	50,000	100,000
Fields of Life	125,000	200,000
Philadelphia Education Fund	5,444	16,615
Train to Be Smart	-	37,720
Buddy Bear Trust	200,000	300,000
Train to be Smart - pledge	330,000	330,000
QUB: McClay Chairs in Medicinal Chemistry/Oncology	204,530	358,917
Young Lives v Cancer	25,000	50,000
Children in Northern Ireland	60,000	25,000
Friends of the Cancer Centre	-	70,000
Action Cancer	20,000	-
Cancer Fund for Children	250,000	-
John Hopkins University	92,761	-
	<b>1,512,735</b>	<b>1,688,252</b>

The above contingent liabilities represent grants committed to projects but are contingent upon the recipient meeting specific criteria in future years. There is no evidence of default on the terms applied.